Literature DB >> 22889770

FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis.

Yu-Yu Lu1, Jin-Hua Chen, Wan-Yu Lin, Ji-An Liang, Hsin-Yi Wang, Shih-Chuan Tsai, Chia-Hung Kao.   

Abstract

AIM: The purpose of the current study was to conduct a systematic review and meta-analysis of the published literature to evaluate the diagnostic accuracy of FDG PET or PET/CT for intramedullary and extramedullary lesions in multiple myeloma.
METHODS: The authors conducted a systematic MEDLINE search of published articles. Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-), and summary receiver operating characteristic curves in the detection of intramedullary and extramedullary lesions in multiple myeloma.
RESULTS: Fourteen studies with a total of 395 patients met the inclusion criteria. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET or PET/CT for the detection of extramedullary lesions in multiple myeloma were 96.0% [95% confidence interval (CI), 79.6%-99.9%], 77.8% (95% CI, 40.0%-97.2%), 3.28 (95% CI, 1.29-8.32), and 0.12 (95% CI, 0.03-0.42), respectively. The pooled estimates of sensitivity, specificity, LR+, and LR- of FDG PET or PET/CT for the detection of intramedullary lesions in multiple myeloma were 61.1% (95% CI, 43.5%-76.9%), 94.1% (95% CI, 71.3%-99.9%), 5.73 (95% CI, 1.53-21.40), and 0.43 (95% CI, 0.28-0.65), respectively.
CONCLUSIONS: Whole-body FDG PET or PET/CT is a valuable imaging tool for the assessment of patients with multiple myeloma, especially for the appraisal of extramedullary involvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889770     DOI: 10.1097/RLU.0b013e31825b2071

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  26 in total

Review 1.  Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Authors:  Gary A Ulaner; C Ola Landgren
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

2.  Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.

Authors:  Francesca Fontana; Xia Ge; Xinming Su; Deep Hathi; Jingyu Xiang; Simone Cenci; Roberto Civitelli; Kooresh I Shoghi; Walter J Akers; Andre D'avignon; Katherine N Weilbaecher; Monica Shokeen
Journal:  Clin Cancer Res       Date:  2016-08-02       Impact factor: 12.531

Review 3.  How We Manage Patients with Plasmacytomas.

Authors:  Despina Fotiou; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 4.  Role of FDG PET in the staging of multiple myeloma.

Authors:  Joao R T Vicentini; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2021-04-04       Impact factor: 2.199

Review 5.  Progress of modern imaging modalities in multiple myeloma.

Authors:  Toshiki Terao; Kosei Matsue
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.490

6.  Abdominal adipose tissue in MGUS and multiple myeloma.

Authors:  Joyce Veld; Elizabeth K O'Donnell; Michaela R Reagan; Andrew J Yee; Martin Torriani; Clifford J Rosen; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2016-06-25       Impact factor: 2.199

Review 7.  ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Authors:  Franco Dammacco; Giuseppe Rubini; Cristina Ferrari; Angelo Vacca; Vito Racanelli
Journal:  Clin Exp Med       Date:  2014-09-14       Impact factor: 3.984

8.  Extramedullary Solitary Plasmacytoma: Demonstrating the Role of 18F-FDG PET Imaging.

Authors:  Archana Gautam; Kamal Kant Sahu; Ahsan Alamgir; Imran Siddiqi; Sikander Ailawadhi
Journal:  J Clin Diagn Res       Date:  2017-04-01

Review 9.  Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?

Authors:  Carmelo Caldarella; Maria Antonietta Isgrò; Ivan Treglia; Giorgio Treglia
Journal:  Int J Hematol       Date:  2012-11-08       Impact factor: 2.490

Review 10.  Applications of PET-MRI in musculoskeletal disease.

Authors:  Feliks Kogan; Stephen M Broski; Daehyun Yoon; Garry E Gold
Journal:  J Magn Reson Imaging       Date:  2018-07       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.